Subcutaneous Ofatumumab in Relapsing Remitting Multiple Sclerosis.
A Randomized, Double-blind, Placebo controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months’ administration of Ofatumumab in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS)
What was tested
Treatment tested
- Ofatumumab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
Cumulative number of new T1 gadolinium-enhancing brain lesions at Week 12 from Week 0 based on MRI scans at Weeks 4, 8, and 12.
MRI lesions
Other measures (1)
•Cumulative number of new T1 Gd-enhancing brain lesions at Week 24 from Week 0 based on MRI scans at Weeks 4, 8, 12, 16, 20, and 24.
MRI lesions
Loading reviews and guidelines…
Related trials
- A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogeni
Phase 2 · Not yet recruiting
Still running
- Switch to Ofatumumab and Level of Immunoglobulins
Recruiting
Still running
- Non-interventional Study of Subcutaneous Ocrelizumab in Persons With R
Recruiting
Still running
- The HIt HArd and hiT Early in Multiple Sclerosis Trial
Phase 2 · Recruiting
Still running
- Brain Imaging and Immune Changes During Remibrutinib Treatment in Mult
Recruiting
Still running
- Study to Assess Effects of Ublituximab in Pediatric Participants With
Phase 2 / Phase 3 · Recruiting
Still running
History
- In scope changed from true to false
Started
Sept 2011